<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329471</url>
  </required_header>
  <id_info>
    <org_study_id>HYMC-16-2011</org_study_id>
    <nct_id>NCT01329471</nct_id>
  </id_info>
  <brief_title>Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hillel Yaffe Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weizmann Institute of Science</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hillel Yaffe Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to elucidate the role of RUNX1 in Acute Myeloid Leukemia (AML),&#xD;
      in particular, the transcriptional regulation of genes by mutated forms of this protein. This&#xD;
      research will study the effect of mutations found in AML patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RUNX1 gene, located at chromosomal band 21q22, is a transcription factor, crucial for&#xD;
      hematopoiesis and the generation of hematopoietic stem cells in the embryo. RUNX1 is the most&#xD;
      frequent target for chromosomal translocation in leukemia. In addition, point mutations in&#xD;
      the RUNX1 gene have been found to constitute an important mode of genetic alteration in&#xD;
      development of leukemia. Recent publications stressing the clinical need for implementing&#xD;
      RUNX1 point mutations as both a diagnostic and unfavorable prognostic marker of AML, have&#xD;
      aroused particular interest in the functional role of RUNX1 in this disease.&#xD;
&#xD;
      In order to pinpoint specific RUNX1 target genes involved in pre-leukemic transformation or&#xD;
      exacerbation of existing leukemia, the investigators plan to compare expression profiles from&#xD;
      human hematopoietic progenitors overexpressing a mutated form of RUNX1with controls (RUNX1&#xD;
      wild-type and knocked-down). In this study the investigators intend to collect blood, after&#xD;
      receiving informed consent, from umbilical cords of neonates born vaginally, in order to&#xD;
      isolate CD34+ hematopoietic progenitors. Human umbilical cord blood contains relatively high&#xD;
      numbers of CD34+ cells, which may be frozen directly after collection and used as a source of&#xD;
      progenitor cells for further culture or direct analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of expression arrays on transfected CD34+ cells</measure>
    <time_frame>One year</time_frame>
    <description>Performance of expression arrays on transfected CD34+ cells (derived from human cord blood), expecting differential gene expression between the wild type RUNX1-transfected cells and mutated RUNX1-transfected cells.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Umbilical cord blood</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Female hospital patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consenting women who have had full-term birth&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systemic disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Ofer Fainaru, MD, PhD</last_name>
      <email>ofer.fainaru@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>March 10, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>April 5, 2011</last_update_submitted>
  <last_update_submitted_qc>April 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Ofer Fainaru</name_title>
    <organization>Hillel Yaffe Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

